337 related articles for article (PubMed ID: 33607081)
21. Performance comparison of the Cobas® Liat® and Cepheid® GeneXpert® systems on SARS-CoV-2 detection in nasopharyngeal swab and posterior oropharyngeal saliva.
Tsang HF; Leung WMS; Chan LWC; Cho WCS; Wong SCC
Expert Rev Mol Diagn; 2021 May; 21(5):515-518. PubMed ID: 33906571
[No Abstract] [Full Text] [Related]
22. Comparative evaluation of the Thermo fisher TaqPath™ COVID-19 combo kit with the Cepheid Xpert® Xpress SARS-CoV-2 assay for detecting SARS-CoV-2 in nasopharyngeal specimens.
Granato PA; Kimball SR; Alkins BR; Cross DC; Unz MM
BMC Infect Dis; 2021 Jun; 21(1):623. PubMed ID: 34193072
[TBL] [Abstract][Full Text] [Related]
23. Application of digital PCR to determine the reliability of Xpert Xpress SARS-CoV-2 assay with envelope (E) gene negative and nucleocapsid (N2) gene positive results.
Wong RC; Wong AH; Ho YI; Siu GK; Lee LK; Leung EC; Lai RW
Diagn Microbiol Infect Dis; 2022 Aug; 103(4):115726. PubMed ID: 35691105
[TBL] [Abstract][Full Text] [Related]
24. Test Agreement between Roche Cobas 6800 and Cepheid GeneXpert Xpress SARS-CoV-2 Assays at High Cycle Threshold Ranges.
Broder K; Babiker A; Myers C; White T; Jones H; Cardella J; Burd EM; Hill CE; Kraft CS
J Clin Microbiol; 2020 Jul; 58(8):. PubMed ID: 32444354
[No Abstract] [Full Text] [Related]
25. Clinical Evaluation of BioFire COVID-19 Test, BioFire Respiratory Panel 2.1, and Cepheid Xpert Xpress SARS-CoV-2 Assays for Sample-to-Answer Detection of SARS-CoV-2.
Park J; Kim SY; Lee J; Hong KH
Genes (Basel); 2023 Jan; 14(1):. PubMed ID: 36672974
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the Xpert Xpress SARS-CoV-2/Flu/RSV Assay for Simultaneous Detection of SARS-CoV-2, Influenza A and B Viruses, and Respiratory Syncytial Virus in Nasopharyngeal Specimens.
Leung EC; Chow VC; Lee MK; Tang KP; Li DK; Lai RW
J Clin Microbiol; 2021 Mar; 59(4):. PubMed ID: 33436456
[TBL] [Abstract][Full Text] [Related]
27. Determination of the cycle threshold value of the Xpert Xpress SARS-CoV-2/Flu/RSV test that corresponds to the presence of infectious SARS-CoV-2 in anterior nasal swabs.
Relich RF; Van Benten K; Lei G-S; Robinson CM; Carozza M; Sahoo MK; Huang C; Solis D; Sibai M; Myers CA; Sikorski C; Balagot C; Yang D; Pinsky BA; Loeffelholz MJ
Microbiol Spectr; 2024 Apr; 12(4):e0390823. PubMed ID: 38466093
[TBL] [Abstract][Full Text] [Related]
28. Parallel testing of 241 clinical nasopharyngeal swabs for the detection of SARS-CoV-2 virus on the Cepheid Xpert Xpress SARS-CoV-2 and the Roche cobas SARS-CoV-2 assays.
Tham JWM; Ng SC; Chai CN; Png S; Tan EJM; Ng LJ; Chua RP; Sani M; Chiang D; Tan KX; Tee NWS; Jureen R; Tan SS; Yan G; Yan B; Lee CK
Clin Chem Lab Med; 2020 Nov; 59(2):e45-e48. PubMed ID: 33554503
[No Abstract] [Full Text] [Related]
29. A Direct Comparison of Enhanced Saliva to Nasopharyngeal Swab for the Detection of SARS-CoV-2 in Symptomatic Patients.
Procop GW; Shrestha NK; Vogel S; Van Sickle K; Harrington S; Rhoads DD; Rubin BP; Terpeluk P
J Clin Microbiol; 2020 Oct; 58(11):. PubMed ID: 32883744
[TBL] [Abstract][Full Text] [Related]
30. Saliva for diagnosis of SARS-CoV-2: First report from India.
Bhattacharya D; Parai D; Rout UK; Dash P; Nanda RR; Dash GC; Kanungo S; Palo SK; Giri S; Choudhary HR; Kshatri JS; Turuk J; Mishra BK; Lenka RK; Dash S; Pati S
J Med Virol; 2021 Apr; 93(4):2529-2533. PubMed ID: 33295640
[TBL] [Abstract][Full Text] [Related]
31. A cost-consequence analysis of the Xpert Xpress CoV-2/Flu/RSV plus test strategy for the diagnosis of influenza-like illnesses.
Davies S; Boller E; Chase J; Beaubrun A; Miller C; Jensen I
J Med Econ; 2024; 27(1):430-441. PubMed ID: 38328858
[TBL] [Abstract][Full Text] [Related]
32. Comparison of commercial assays and laboratory developed tests for detection of SARS-CoV-2.
Dust K; Hedley A; Nichol K; Stein D; Adam H; Karlowsky JA; Bullard J; Van Caeseele P; Alexander DC
J Virol Methods; 2020 Nov; 285():113970. PubMed ID: 32920028
[TBL] [Abstract][Full Text] [Related]
33. Tuberculosis/COVID-19 co-infection detected in a single sputum sample using a rapid molecular test.
Guirelli AO; Bispo TR; Colpas DR; de Campos IB; Chimara E; Cergole-Novella MC; Rodart IF; Dos Santos Candido V; Segura-Ramírez PJ; Dos Santos Menezes Gaiotto Daros V; Dos Santos Carmo AM
Braz J Microbiol; 2022 Jun; 53(2):633-639. PubMed ID: 35107805
[TBL] [Abstract][Full Text] [Related]
34. Impact of G29179T mutation on two commercial PCR assays for SARS-CoV-2 detection.
Kami W; Kinjo T; Hashioka H; Arakaki W; Uechi K; Takahashi A; Oki H; Tanaka K; Motooka D; Nakamura S; Nakamatsu M; Maeda S; Yamamoto K; Fujita J
J Virol Methods; 2023 Apr; 314():114692. PubMed ID: 36796678
[TBL] [Abstract][Full Text] [Related]
35. Extraction-Free Methods for the Detection of SARS-CoV-2 by Reverse Transcription-PCR: a Comparison with the Cepheid Xpert Xpress SARS-CoV-2 Assay across Two Medical Centers.
Cameron A; Pecora ND; Pettengill MA
J Clin Microbiol; 2021 Jan; 59(2):. PubMed ID: 33184055
[No Abstract] [Full Text] [Related]
36. Detection of Severe Acute Respiratory Syndrome Coronavirus 2 on Self-Collected Saliva or Anterior Nasal Specimens Compared With Healthcare Personnel-Collected Nasopharyngeal Specimens.
Marx GE; Biggerstaff BJ; Nawrocki CC; Totten SE; Travanty EA; Burakoff AW; Scott T; De Hey JC; Carlson JJ; Wendel KA; Harcourt JL; Tamin A; Thomas JD; Rowan SE; ;
Clin Infect Dis; 2021 Jul; 73(Suppl 1):S65-S73. PubMed ID: 33912930
[TBL] [Abstract][Full Text] [Related]
37. Asymptomatic Patient Testing After 10:1 Pooling Using the Xpert Xpress SARS-CoV-2 Assay.
Procop GW; Tuohy M; Ramsey C; Rhoads DD; Rubin BP; Figler R
Am J Clin Pathol; 2021 Mar; 155(4):522-526. PubMed ID: 33399200
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of Self-Collected Midturbinate Nasal Swabs and Saliva for Detection of SARS-CoV-2 RNA.
Boerger AC; Buckwalter S; Fernholz EC; Jannetto PJ; Binnicker MJ; Reed K; Walchak R; Woodliff E; Johnson M; Pritt BS
J Clin Microbiol; 2021 Aug; 59(9):e0084821. PubMed ID: 34132579
[TBL] [Abstract][Full Text] [Related]
39. Design and Implementation of Improved SARS-CoV-2 Diagnostic Assays To Mitigate the Impact of Genomic Mutations on Target Failure: the Xpert Xpress SARS-CoV-2 Experience.
Burns BL; Moody D; Tu ZJ; Nakitandwe J; Brock JE; Bosler D; Mitchell SL; Loeffelholz MJ; Rhoads DD
Microbiol Spectr; 2022 Dec; 10(6):e0135522. PubMed ID: 36255326
[TBL] [Abstract][Full Text] [Related]
40. Copan eNAT Transport System To Address Challenges in COVID-19 Diagnostics in Regions with Limited Testing Access.
Richard-Greenblatt M; Comar CE; Flevaud L; Berti M; Harris RM; Weiss SR; Glaser L
J Clin Microbiol; 2021 Apr; 59(5):. PubMed ID: 33579730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
